Literature DB >> 12195345

Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa.

Thea K Fischer1, Palle Valentiner-Branth, Hans Steinsland, Michael Perch, Gina Santos, Peter Aaby, Kåre Mølbak, Halvor Sommerfelt.   

Abstract

To study the natural history of rotavirus infection and to determine the protection it confers against reinfection and diarrhea, 200 newborns in Guinea-Bissau were prospectively followed for up to 2 years. Rotavirus was detected in stool specimens collected weekly. By age 2 years, the incidence of primary rotavirus infection was 74%. In the first 3 months of life, 17% of the infections were diarrhea associated, compared with 60% at 9-11 months; after age 18 months, all infections were asymptomatic. A primary infection conferred 52% (95% confidence interval [CI], 16% to 73%) and 70% (95% CI, 29% to 87%) protection against subsequent rotavirus infection and rotavirus diarrhea, respectively. The protection was 66% (95% CI, 24% to 85%) against reinfection within the same epidemic, compared with 34% (95% CI, -29% to 67%) against reinfection in any subsequent epidemic. The high level of protection against symptomatic rotavirus infection provides an important incentive for development of a rotavirus vaccine.

Entities:  

Mesh:

Year:  2002        PMID: 12195345     DOI: 10.1086/342294

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  Rotavirus particles can survive storage in ambient tropical temperatures for more than 2 months.

Authors:  Thea K Fischer; Hans Steinsland; Palle Valentiner-Branth
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

Review 2.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

3.  Reinfection of adult cattle with rotavirus B during repeated outbreaks of epidemic diarrhea.

Authors:  Michiko Hayashi; Toshiaki Murakami; Yoshizumi Kuroda; Hikaru Takai; Hisahiro Ide; Ainani Awang; Tohru Suzuki; Ayako Miyazaki; Makoto Nagai; Hiroshi Tsunemitsu
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

4.  Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study.

Authors:  Aisleen Bennett; Louisa Pollock; Naor Bar-Zeev; Joseph A Lewnard; Khuzwayo C Jere; Benjamin Lopman; Miren Iturriza-Gomara; Virginia E Pitzer; Nigel A Cunliffe
Journal:  Lancet Infect Dis       Date:  2020-12-24       Impact factor: 25.071

5.  Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study.

Authors:  Elizabeth T Rogawski; James A Platts-Mills; E Ross Colgate; Rashidul Haque; K Zaman; William A Petri; Beth D Kirkpatrick
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

Review 6.  Rotavirus vaccines: update on global impact and future priorities.

Authors:  Catherine Yen; Jacqueline E Tate; Manish M Patel; Margaret M Cortese; Benjamin Lopman; Jessica Fleming; Kristen Lewis; Baoming Jiang; Jon Gentsch; Duncan Steele; Umesh D Parashar
Journal:  Hum Vaccin       Date:  2011-12-01

Review 7.  Rotavirus vaccines: an overview.

Authors:  Penelope H Dennehy
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

8.  Naturally Acquired Immunity Against Rotavirus Infection and Gastroenteritis in Children: Paired Reanalyses of Birth Cohort Studies.

Authors:  Joseph A Lewnard; Benjamin A Lopman; Umesh D Parashar; Naor Bar-Zeev; Prasanna Samuel; M Lourdes Guerrero; Guillermo M Ruiz-Palacios; Gagandeep Kang; Virginia E Pitzer
Journal:  J Infect Dis       Date:  2017-08-01       Impact factor: 5.226

9.  Rotavirus shedding in symptomatic and asymptomatic children using reverse transcription-quantitative PCR.

Authors:  Indrani Mukhopadhya; Rajiv Sarkar; Vipin Kumar Menon; Sudhir Babji; Anu Paul; Priya Rajendran; Thuppal V Sowmyanarayanan; Prabhakar D Moses; Miren Iturriza-Gomara; James J Gray; Gagandeep Kang
Journal:  J Med Virol       Date:  2013-06-17       Impact factor: 2.327

10.  Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis.

Authors:  Johnie Rose; Rachael L Hawthorn; Brook Watts; Mendel E Singer
Journal:  BMJ       Date:  2009-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.